Protective immunity against tuberculosis: what does it look like and how do we find it?

Current Opinion in Immunology

Volumn 48, Issue , 2017, Pages 44-50

  Huang, Lu ^a   Russell, David G ^a  

^a Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR A; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG; BCG VACCINE;

ASSAY; BACTERIAL FITNESS; BACTERIAL GROWTH; BACTERIAL PHENOMENA AND FUNCTIONS; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE COURSE; GLYCOLYSIS; HUMAN; IMMUNITY; INTERFERON GAMMA RELEASE ASSAY; INTERSTITIAL MACROPHAGE; LIPID METABOLISM; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MONOCYTE; MYCOBACTERIAL GROWTH INHIBITION ASSAY; NEUTROPHIL; NONHUMAN; REVIEW; TUBERCULOSIS; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 85027532390     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2017.08.001     Document Type: Review

References (57)

1. Tameris, M.D., Hatherill, M., Landry, B.S., Scriba, T.J., Snowden, M.A., Lockhart, S., Shea, J.E., McClain, J.B., Hussey, G.D., Hanekom, W.A., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381 (2013), 1021–1028.
2. Houben, R.M., Dodd, P.J., The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med, 13, 2016, e1002152 The penetrance of the Mtb in the human population (1/3) is an oft quoted statistic with little evidential basis. This represents one of the few studies that make an extremely valid and credible assessment of the actual bacterial burden in the human population.
3. World Health Organization, Global Tuberculosis Report 2016., 2016.
4. North, R.J., Jung, Y.J., Immunity to tuberculosis. Annu Rev Immunol 22 (2004), 599–623.
5. Russell, D.G., Barry, C.E. III, Flynn, J.L., Tuberculosis: what we don't know can, and does, hurt us. Science 328 (2010), 852–856.
6. Flynn, J.L., Gideon, H.P., Mattila, J.T., Lin, P.L., Immunology studies in non-human primate models of tuberculosis. Immunol Rev 264 (2015), 60–73.
7. Kim, M.J., Wainwright, H.C., Locketz, M., Bekker, L.G., Walther, G.B., Dittrich, C., Visser, A., Wang, W., Hsu, F.F., Wiehart, U., et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2 (2010), 258–274.
8. Lin, P.L., Ford, C.B., Coleman, M.T., Myers, A.J., Gawande, R., Ioerger, T., Sacchettini, J., Fortune, S.M., Flynn, J.L., Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20 (2014), 75–79.
9. Marino, S., Cilfone, N.A., Mattila, J.T., Linderman, J.J., Flynn, J.L., Kirschner, D.E., Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection. Infect Immun 83 (2015), 324–338 This was the study that accessed the phenotypic balance of macrophage subsets in NHP granulomas and proposed that it was the relative ratio of classical activated (M1) versus alternatively activated (M2) phagocytes that determined disease progression at the level of the individual granuloma.
10. Russell, D.G., Who puts the tubercle in tuberculosis?. Nat Rev Microbiol 5 (2007), 39–47.
11. McNab, F.W., Berry, M.P., Graham, C.M., Bloch, S.A., Oni, T., Wilkinson, K.A., Wilkinson, R.J., Kon, O.M., Banchereau, J., Chaussabel, D., et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol 41 (2011), 1941–1947.
12. Berry, M.P., Graham, C.M., McNab, F.W., Xu, Z., Bloch, S.A., Oni, T., Wilkinson, K.A., Banchereau, R., Skinner, J., Wilkinson, R.J., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466 (2010), 973–977.
13. Petruccioli, E., Scriba, T.J., Petrone, L., Hatherill, M., Cirillo, D.M., Joosten, S.A., Ottenhoff, T.H., Denkinger, C.M., Goletti, D., Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 48 (2016), 1751–1763 A recent and useful review discussing the current status and value of early biomarkers of risk and disease progression.
14. Cooper, A.M., Dalton, D.K., Stewart, T.A., Griffin, J.P., Russell, D.G., Orme, I.M., Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178 (1993), 2243–2247.
15. Flynn, J.L., Chan, J., Triebold, K.J., Dalton, D.K., Stewart, T.A., Bloom, B.R., An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 (1993), 2249–2254.
16. Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette–Guerin infection. N Engl J Med 335 (1996), 1956–1961.
17. Dobler, C.C., Biologic agents and tuberculosis. Microbiol Spectr, 2016, 4.
18. Khader, S.A., Bell, G.K., Pearl, J.E., Fountain, J.J., Rangel-Moreno, J., Cilley, G.E., Shen, F., Eaton, S.M., Gaffen, S.L., Swain, S.L., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8 (2007), 369–377.
19. Gopal, R., Monin, L., Slight, S., Uche, U., Blanchard, E., Fallert Junecko, B.A., Ramos-Payan, R., Stallings, C.L., Reinhart, T.A., Kolls, J.K., et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog, 10, 2014, e1004099.
20. Dhiman, R., Periasamy, S., Barnes, P.F., Jaiswal, A.G., Paidipally, P., Barnes, A.B., Tvinnereim, A., Vankayalapati, R., NK1.1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis. J Immunol 189 (2012), 897–905.
21. Dieli, F., Troye-Blomberg, M., Ivanyi, J., Fournie, J.J., Krensky, A.M., Bonneville, M., Peyrat, M.A., Caccamo, N., Sireci, G., Salerno, A., Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 184 (2001), 1082–1085.
22. Bhatt, K., Verma, S., Ellner, J.J., Salgame, P., Quest for correlates of protection against tuberculosis. Clin Vaccine Immunol 22 (2015), 258–266.
23. Goletti, D., Petruccioli, E., Joosten, S.A., Ottenhoff, T.H., Tuberculosis biomarkers: from diagnosis to protection. Infect Dis Rep, 8, 2016, 6568.
24. Kaufmann, S.H., Fortune, S., Pepponi, I., Ruhwald, M., Schrager, L.K., Ottenhoff, T.H., TB biomarkers, TB correlates and human challenge models: new tools for improving assessment of new TB vaccines. Tuberculosis (Edinb) 99:Suppl 1 (2016), S8–S11.
25. Tanner, R., O'Shea, M.K., Fletcher, H.A., McShane, H., In vitro mycobacterial growth inhibition assays: a tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy. Vaccine 34 (2016), 4656–4665.
26. Fletcher, H.A., Tanner, R., Wallis, R.S., Meyer, J., Manjaly, Z.R., Harris, S., Satti, I., Silver, R.F., Hoft, D., Kampmann, B., et al. Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. Clin Vaccine Immunol 20 (2013), 1683–1689.
27. Srivastava, S., Ernst, J.D., Desvignes, L., Beyond macrophages: the diversity of mononuclear cells in tuberculosis. Immunol Rev 262 (2014), 179–192.
28. Wolf, A.J., Linas, B., Trevejo-Nunez, G.J., Kincaid, E., Tamura, T., Takatsu, K., Ernst, J.D., Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 179 (2007), 2509–2519.
29. Hohl, T.M., Rivera, A., Lipuma, L., Gallegos, A., Shi, C., Mack, M., Pamer, E.G., Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal infection. Cell Host Microbe 6 (2009), 470–481.
30. Samstein, M., Schreiber, H.A., Leiner, I.M., Susac, B., Glickman, M.S., Pamer, E.G., Essential yet limited role for CCR2(+) inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming. Elife, 2, 2013, e01086.
31. Wolf, A.J., Desvignes, L., Linas, B., Banaiee, N., Tamura, T., Takatsu, K., Ernst, J.D., Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205 (2008), 105–115.
32. Skold, M., Behar, S.M., Tuberculosis triggers a tissue-dependent program of differentiation and acquisition of effector functions by circulating monocytes. J Immunol 181 (2008), 6349–6360.
33. Leemans, J.C., Juffermans, N.P., Florquin, S., van Rooijen, N., Vervoordeldonk, M.J., Verbon, A., van Deventer, S.J., van der Poll, T., Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 166 (2001), 4604–4611.
34. Leemans, J.C., Thepen, T., Weijer, S., Florquin, S., van Rooijen, N., van de Winkel, J.G., van der Poll, T., Macrophages play a dual role during pulmonary tuberculosis in mice. J Infect Dis 191 (2005), 65–74.
35. Antonelli, L.R., Gigliotti Rothfuchs, A., Goncalves, R., Roffe, E., Cheever, A.W., Bafica, A., Salazar, A.M., Feng, C.G., Sher, A., Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 120 (2010), 1674–1682.
36. Mattila, J.T., Ojo, O.O., Kepka-Lenhart, D., Marino, S., Kim, J.H., Eum, S.Y., Via, L.E., Barry, C.E. III, Klein, E., Kirschner, D.E., et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 191 (2013), 773–784.
37. Marino, S., Gideon, H.P., Gong, C., Mankad, S., McCrone, J.T., Lin, P.L., Linderman, J.J., Flynn, J.L., Kirschner, D.E., Computational and empirical studies predict Mycobacterium tuberculosis-specific T cells as a biomarker for infection outcome. PLoS Comput Biol, 12, 2016, e1004804.
38. Gideon, H.P., Phuah, J., Myers, A.J., Bryson, B.D., Rodgers, M.A., Coleman, M.T., Maiello, P., Rutledge, T., Marino, S., Fortune, S.M., et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog, 11, 2015, e1004603.
39. Bertolini, T.B., de Souza, A.I., Gembre, A.F., Pineros, A.R., Prado Rde, Q., Silva, J.S., Ramalho, L.N., Bonato, V.L., Genetic background affects the expansion of macrophage subsets in the lungs of Mycobacterium tuberculosis-infected hosts. Immunology 148 (2016), 102–113.
40. Pineros, A.R., Campos, L.W., Fonseca, D.M., Bertolini, T.B., Gembre, A.F., Prado, R.Q., Alves-Filho, J.C., Ramos, S.G., Russo, M., Bonato, V.L., M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection. Sci Rep, 7, 2017, 41240.
41. Abramovitch, R.B., Rohde, K.H., Hsu, F.F., Russell, D.G., aprABC: a Mycobacterium tuberculosis complex-specific locus that modulates pH-driven adaptation to the macrophage phagosome. Mol Microbiol 80 (2011), 678–694.
42. Homolka, S., Niemann, S., Russell, D.G., Rohde, K.H., Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog, 6, 2010, e1000988.
43. Rohde, K.H., Abramovitch, R.B., Russell, D.G., Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2 (2007), 352–364.
44. Rohde, K.H., Veiga, D.F., Caldwell, S., Balazsi, G., Russell, D.G., Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog, 8, 2012, e1002769.
45. Sukumar, N., Tan, S., Aldridge, B.B., Russell, D.G., Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog, 10, 2014, e1004394 This study was the first to utilize bacteria fitness reporters to relate bacteria fitness at site of infection with host immune response in naïve and vaccinated experimental infections.
46. Tan, S., Sukumar, N., Abramovitch, R.B., Parish, T., Russell, D.G., Mycobacterium tuberculosis responds to chloride and pH as synergistic cues to the immune status of its host cell. PLoS Pathog, 9, 2013, e1003282.
47. Liu, Y., Tan, S., Huang, L., Abramovitch, R.B., Rohde, K.H., Zimmerman, M.D., Chen, C., Dartois, V., VanderVen, B.C., Russell, D.G., Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo. J Exp Med 213 (2016), 809–825 This study demonstrated the functional linkage between the induction of drug tolerance and the immune activation status of the host phagocytes both in vitro and in vivo.
48. VanderVen, B.C., Huang, L., Rohde, K.H., Russell, D.G., The minimal unit of infection: Mycobacterium tuberculosis in the macrophage. Microbiol Spectr, 2016, 4.
49. Mills, E.L., Kelly, B., O'Neill, L.A.J., Mitochondria are the powerhouses of immunity. Nat Immunol 18 (2017), 488–498.
50. Van den Bossche, J., O'Neill, L.A., Menon, D., Macrophage immunometabolism: where are we (going)?. Trends Immunol, 2017.
51. Shi, L., Salamon, H., Eugenin, E.A., Pine, R., Cooper, A., Gennaro, M.L., Infection with Mycobacterium tuberculosis induces the Warburg effect in mouse lungs. Sci Rep, 5, 2015, 18176.
52. Gleeson, L.E., Sheedy, F.J., Palsson-McDermott, E.M., Triglia, D., O'Leary, S.M., O'Sullivan, M.P., O'Neill, L.A., Keane, J., Cutting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication. J Immunol 196 (2016), 2444–2449.
53. Lee, W., VanderVen, B.C., Fahey, R.J., Russell, D.G., Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 288 (2013), 6788–6800.
54. Peyron, P., Vaubourgeix, J., Poquet, Y., Levillain, F., Botanch, C., Bardou, F., Daffe, M., Emile, J.F., Marchou, B., Cardona, P.J., et al. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog, 4, 2008, e1000204.
55. Russell, D.G., Cardona, P.J., Kim, M.J., Allain, S., Altare, F., Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 10 (2009), 943–948.
56. VanderVen, B.C., Fahey, R.J., Lee, W., Liu, Y., Abramovitch, R.B., Memmott, C., Crowe, A.M., Eltis, L.D., Perola, E., Deininger, D.D., et al. Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment. PLoS Pathog, 11, 2015, e1004679 This study details completion of a large empirical chemical screen against intracellular Mtb that identified bacterial cholesterol metabolism as critical to intracellular survival and growth. The result highlights the intimate association between host cell immune status and metabolism, and bacterial nutrient acquisition.
57. Feingold, K.R., Shigenaga, J.K., Kazemi, M.R., McDonald, C.M., Patzek, S.M., Cross, A.S., Moser, A., Grunfeld, C., Mechanisms of triglyceride accumulation in activated macrophages. J Leukoc Biol 92 (2012), 829–839.